Document is current
Any future updates will be listed below
-
Authors
Halliday, Jennifer A. https://orcid.org/0000-0003-1156-279X
Holmes-Truscott, Elizabeth https://orcid.org/0000-0001-9139-4663
Thuraisingam, Sharmala https://orcid.org/0000-0002-9450-1302
Søholm, Uffe https://orcid.org/0000-0003-0848-9421
Chatterton, Mary Lou https://orcid.org/0000-0003-4902-9448
Russell-Green, Sienna
O, Eric
Andrikopoulos, Sof
Black, Taryn
Davidson, Susan
Noonan, Glen
Scibilia, Renza
Hagger, Virginia https://orcid.org/0000-0003-3845-2814
Hendrieckx, Christel https://orcid.org/0000-0002-0075-828X
Mihalopoulos, Cathrine https://orcid.org/0000-0002-7127-9462
Shaw, James A. M. https://orcid.org/0000-0002-2893-3211
Versace, Vincent L. https://orcid.org/0000-0002-8514-1763
Zoungas, Sophia https://orcid.org/0000-0003-2672-0949
Skinner, Timothy C. https://orcid.org/0000-0002-0018-6963
Speight, Jane https://orcid.org/0000-0002-1204-6896
,
Baptista, Shaira
Prasertsung, Chatpakorn
Robinson, Alison
- License Information
-
More Information
Article History
Received: 23 August 2024
Accepted: 14 October 2024
First Online: 29 October 2024
Declarations
:
: This study is approved by Deakin University Human Research Ethics Committee (DUHREC ref: 2023–132). Informed consent to participate will be obtained from all participants. A model consent form is provided in Additional File 3.
: JAH reports speaker honoraria from Roche Diabetes Care, paid to her institution, for a one-off presentation unrelated to the HypoPAST protocol. EH-T has undertaken research funded by an unrestricted educational grant from Abbott Diabetes Care, AstraZeneca and Sanofi, Australia; received speaker fees from Novo Nordisk and Roche; and has served on an advisory board for AstraZeneca. All honoraria paid to her institution. GN reports that he is on the Board of Directors at the Royal Women’s Hospital, Melbourne. VLV reports that he is on the Board of Directors of the Australian Rural Health Education Network (ARHEN). SZ reports payment to institution (Monash University) from Amgen Australia Pty Ltd, Eli Lilly Australia, MSD Australia Pty Ltd, AstraZeneca Pty Ltd, Novo Nordisk, and Sanofi for work unrelated to the HypoPAST protocol. JAMS has received consultancy fees as a member of a Mogrify Limited and RegMedXB International Scientific Advisory Boards. JSp has served on advisory boards for Janssen, Medtronic, Omnipod, Roche Diabetes Care and Sanofi Diabetes; received unrestricted educational grants and in-kind support from Abbott Diabetes Care, AstraZeneca, Medtronic, Roche Diabetes Care, and Sanofi Diabetes; received sponsorship to attend educational meetings from Medtronic, Roche Diabetes Care and Sanofi Diabetes, and consultancy income or speaker fees from Abbott Diabetes Care, AstraZeneca, Insulet, Medtronic, Novo Nordisk, Roche Diabetes Care and Sanofi Diabetes. All honoraria paid to her institution. JSp is also the copyright holder of the HypoA-Q used in this study. TCS reports that he has received funding from Roche Diagnostics for research projects, and been CI on grants with Roche as a co-funder. TCS has sat on Advisory Boards for Novo Nordisk (last in 2020), AstraZeneca, Eli Lilly and Sanofi (all of these pre-2007). CH, MLC, EO, ST, SR-G and CM declare that they have no competing interests.
